Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
12.08. | AEON Biopharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
12.08. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
AEON BIOPHARMA Aktie jetzt für 0€ handeln | |||||
13.06. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
11.06. | AEON Biopharma, Inc. - 10-Q/A, Quarterly Report | 1 | SEC Filings | ||
11.06. | AEON Biopharma, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
23.05. | AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | 168 | GlobeNewswire (Europe) | IRVINE, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
20.05. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
15.05. | AEON Biopharma GAAP EPS of $2.28 | 1 | Seeking Alpha | ||
14.05. | AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update | 134 | GlobeNewswire (Europe) | - Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 - - Pursuing a 351(k)... ► Artikel lesen | |
25.04. | NYSE American accepts AEON Biopharma's plan to regain listing | 1 | Seeking Alpha | ||
25.04. | AEON Biopharma erhält Zustimmung der NYSE American für Compliance-Plan | 1 | Investing.com Deutsch | ||
25.04. | AEON Biopharma gets NYSE American nod for compliance plan | 1 | Investing.com | ||
25.04. | AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance | 694 | GlobeNewswire (Europe) | IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
21.04. | AEON Biopharma ernennt Rob Bancroft zum neuen CEO | 2 | Investing.com Deutsch | ||
21.04. | AEON Biopharma names Rob Bancroft as new CEO | 1 | Investing.com | ||
21.04. | AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | 123 | GlobeNewswire (Europe) | IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
21.04. | AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer | 685 | GlobeNewswire (Europe) | IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
21.04. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
08.04. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
27.03. | AEON Biopharma announces leadership change amid growth strategy | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ALTERITY THERAPEUTICS | 0,006 | 0,00 % | ALTERITY THERAPEUTICS LIMITED: Corporate Governance Statement | ||
BIOCURE TECHNOLOGY | 0,021 | 0,00 % | Biocure Technology Inc (2): Biocure shareholders approve all matters at AGM | ||
QIAGEN | 39,420 | -0,57 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
BEAM THERAPEUTICS | 16,850 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 24,400 | 0,00 % | H.C. Wainwright hebt Kursziel für Summit Therapeutics auf 50 US-Dollar an | ||
AMYLYX PHARMACEUTICALS | 9,420 | 0,00 % | Amylyx stoppt PSP-Programm - Goldman Sachs bleibt bei Kaufempfehlung | ||
AVIDITY BIOSCIENCES | 48,590 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,860 | 0,00 % | Recursion Pharmaceuticals, Inc. (RXRX) Expands Rare Disease Pipeline with REV102 Acquisition | ||
89BIO | 9,420 | 0,00 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
ITEOS THERAPEUTICS | 10,165 | 0,00 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
BIONTECH | 87,50 | +0,23 % | UBS stuft Biontech auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Biontech auf "Neutral" mit einem Kursziel von 115 US-Dollar belassen. Die Wachstumsaussichten für Comirnaty seien angesichts sich weltweit... ► Artikel lesen | |
DYNE THERAPEUTICS | 13,745 | 0,00 % | Dyne Therapeutics stock rises after Raymond James upgrade to Strong Buy | ||
COGNITION THERAPEUTICS | 2,470 | 0,00 % | Cognition Therapeutics, Inc.: Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement | PURCHASE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative... ► Artikel lesen | |
THARIMMUNE | 6,020 | 0,00 % | Tharimmune (THUR) Tumbles 20.7% on $5-Million Share Sale | ||
MINERALYS THERAPEUTICS | 15,220 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen |